Page 261 - சரி செய்யப்பட்டது வருமானம் அழித்தல் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Adamas Pharma - Starting The Year Off Right? WASHINGTON (dpa-AFX) - Shares of Adamas Pharmaceuticals Inc. (ADMS) have recovered 140% from their 52-week low of $1.90 recorded on Mar.18, 2020, and trade around $4.50. Adamas is a commercial-stage pharmaceutical company with a growing portfolio of therapies for neurological diseases. The company s flagship product is GOCOVRI, a FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medicines. The sales of GOCOVRI have increased over the years ever since its launch in the fourth quarter of 2017. The drug raked in sales of $568 thousand in 2017; $34.05 million in 2018; $54.64 million in 2019; and $51.5 million in the nine months ended Sep.30, 2020.

United statesNeil mcfarlaneOsmotica pharmaceuticalCalifornia state courtCalifornia superior courtOsmotica pharmaceuticalsAdamas pharmaceuticals incAdamas pharmaceuticalsChief executive officerCalifornia stateAdam asஒன்றுபட்டது மாநிலங்களில்நீல் மக்‌ஃபார்‌ல்யாந்கலிஃபோர்னியா நிலை நீதிமன்றம்கலிஃபோர்னியா உயர்ந்தது நீதிமன்றம்அட்மாஸ் மருந்துகள் இன்க்